Key facts
- Coldplasmatech’s last known valuation is $124.0M (Feb 2025).
- It has raised $27.9M; the latest was Later Stage VC ($19.9M) in Feb 2025.
- Notable investors include BIF Partners, EIT Health, Leibniz Institute For Science And Mathematics Education, Mittelständische Beteiligungsgesellschaft Mecklenburg-Vorpommern, Royal Biologics — 7 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for Coldplasmatech
- ·The full record, as it builds
Funding rounds
No funding rounds for Coldplasmatech are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Coldplasmatech
Developer of a cold atmospheric plasma therapy platform designed to support infection control and accelerate healing in complex wounds. The company offers a modular system combining a plasma therapy device and application patch that integrates into standard clinical workflows and can be used alone or alongside negative pressure wound therapy and tissue or skin grafting, enabling hospitals, wound care centers, and burn units to manage wounds of varying sizes and depths with improved treatment consistency.
- Sector
- Healthcare
- HQ
- Greifswald, Germany
- Employees
- 20
- Website
- coldplasmatech.com/
- Ownership
- Privately Held (backing)
Coldplasmatech doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Coldplasmatech shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Coldplasmatech in its N-PORT filings yet. We sweep new filings monthly.